Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles

Vaccine

Volumn 32, Issue 46, 2014, Pages 6084-6090

  Ormazábal, Maximiliano ^a   Bartel, Erika ^a   Gaillard, María Emilia ^a   Bottero, Daniela ^a   Errea, Agustina ^a   Zurita, M Eugenia ^a   Moreno, Griselda ^a   Rumbo, Martin ^a   Castuma, Celina ^a   Flores, Dario ^a   Martín, María Julia ^a   Hozbor, Daniela ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

Author keywords

Acellular vaccine; Avirulent phase; Bordetella pertussis; OMVs; Whooping cough

Indexed keywords

ACELLULAR VACCINE; CROSS REACTING ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INTERLEUKIN 6; PERTACTIN; PERTUSSIS TOXIN; VIRULENCE FACTOR; BACTERIAL ANTIGEN; BORDETELLA VIRULENCE FACTOR; OUTER MEMBRANE PROTEIN; PERTUSSIS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG EFFICACY; FEMALE; GEL ELECTROPHORESIS; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEMBRANE VESICLE; MOUSE; NONHUMAN; OUTER MEMBRANE; PERTUSSIS; PROTEIN CONTENT; TRANSMISSION ELECTRON MICROSCOPY; VACCINATION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; WHOOPING COUGH;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; FEMALE; MICE, INBRED BALB C; PERTUSSIS TOXIN; PERTUSSIS VACCINE; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 84907966985     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.084     Document Type: Article

References (38)

1. Cherry J.D. Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease. N Engl J Med 2012, 367:785-787.
2. Hewlett E.L., Edwards K.M. Clinical practice. Pertussis-not just for kids. N Engl J Med 2005, 352:1215-1222.
3. von Konig C.H., Halperin S., Riffelmann M., Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002, 2:744-750.
4. Mooi F.R., NA V.D.M., De Melker H.E. Pertussis resurgence: waning immunity and pathogen adaptation-two sides of the same coin. Epidemiol Infect 2014, 142:685-694.
5. Asensio C.J., Gaillard M.E., Moreno G., Bottero D., Zurita E., Rumbo M., et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 2011, 29:1649-1656.
6. Ross P.J., Sutton C.E., Higgins S., Allen A.C., Walsh K., Misiak A., et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 2013, 9:e1003264.
7. Gaillard M.E., Bottero D., Errea A., Ormazabal M., Zurita M.E., Moreno G., et al. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes. Vaccine 2014, 32:931-937.
8. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
9. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997, 350:1569-1577.
10. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984, 1:122-126.
11. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18:326-382.
12. Roberts M., Bacon A., Rappuoli R., Pizza M., Cropley I., Douce G., et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun 1995, 63:2100-2108.
13. Samore M.H., Siber G.R. Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone. Vaccine 1996, 14:290-297.
14. Ryan M., McCarthy L., Rappuoli R., Mahon B.P., Mills K.H. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int Immunol 1998, 10:651-662.
15. Shive C.L., Hofstetter H., Arredondo L., Shaw C., Forsthuber T.G. The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells. Eur J Immunol 2000, 30:2422-2431.
16. Nasso M., Fedele G., Spensieri F., Palazzo R., Costantino P., Rappuoli R., et al. Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10-dependent mechanisms. J Immunol 2009, 183:1892-1899.
17. Hellwig S.M., Rodriguez M.E., Berbers G.A., van de Winkel J.G., Mooi F.R. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis 2003, 188:738-742.
18. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16:1901-1906.
19. Bottero D., Gaillard M.E., Fingermann M., Weltman G., Fernandez J., Sisti F., et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol: CVI 2007, 14:1490-1498.
20. Antoine R., Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun 1990, 58:1518-1526.
21. Roberts M., Fairweather N.F., Leininger E., Pickard D., Hewlett E.L., Robinson A., et al. Construction and characterization of Bordetella pertussis mutants lacking the vir-regulated P.69 outer membrane protein. Mol Microbiol 1991, 5:1393-1404.
22. Weiss A.A., Falkow S. Genetic analysis of phase change in Bordetella pertussis. Infect Immun 1984, 43:263-269.
23. Hozbor D., Rodriguez M.E., Fernandez J., Lagares A., Guiso N., Yantorno O. Release of outer membrane vesicles from Bordetella pertussis. Curr Microbiol 1999, 38:273-278.
24. Roberts R., Moreno G., Bottero D., Gaillard M.E., Fingermann M., Graieb A., et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 2008, 26:4639-4646.
25. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
26. Bottero D., Gaillard M.E., Basile L.A., Fritz M., Hozbor D.F. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America. J Appl Microbiol 2012, 112:1266-1276.
27. Asensio C.J., Gaillard M.E., Moreno G., Bottero D., Zurita E., Rumbo M., et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 2010, 29:1649-1656.
28. Geurtsen J., Banus H.A., Gremmer E.R., Ferguson H., de la Fonteyne-Blankestijn L.J., Vermeulen J.P., et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol: CVI 2007, 14:821-829.
29. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16:1907-1916.
30. Leininger E., Roberts M., Kenimer J.G., Charles I.G., Fairweather N., Novotny P., et al. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci USA 1991, 88:345-349.
31. Leininger E., Ewanowich C.A., Bhargava A., Peppler M.S., Kenimer J.G., Brennan M.J. Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin. Infect Immun 1992, 60:2380-2385.
32. Pawloski L.C., Queenan A.M., Cassiday P.K., Lynch A.S., Harrison M.J., Shang W., et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol: CVI 2014, 21:119-125.
33. Otsuka N., Han H.J., Toyoizumi-Ajisaka H., Nakamura Y., Arakawa Y., Shibayama K., et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PloS One 2012, 7:e31985.
34. Lam C., Octavia S., Ricafort L., Sintchenko V., Gilbert G.L., Wood N., et al. Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia. Emerg Infect Dis 2014, 20:626-633.
35. Stenson T.H., Peppler M.S. Identification of two bvg-repressed surface proteins of Bordetella pertussis. Infect Immun 1995, 63:3780-3789.
36. Finn T.M., Li Z., Kocsis E. Identification of a Bordetella pertussis bvg-regulated porin-like protein. J Bacteriol 1995, 177:805-809.
37. Liu C., Chen Z., Tan C., Liu W., Xu Z., Zhou R., et al. Immunogenic characterization of outer membrane porins OmpC and OmpF of porcine extraintestinal pathogenic Escherichia coli. FEMS Microbiol Lett 2012, 337:104-111.
38. Burns D.L., Gould-Kostka J.L., Kessel M., Arciniega J.L. Purification and immunological characterization of a GroEL-like protein from Bordetella pertussis. Infect Immun 1991, 59:1417-1422.